DreaMed wins FDA clearance for AI insulin recommendation technology - Israel News - Jerusalem Post

A person receives a test for diabetes during Care Harbor LA free medical clinic in Los Angeles, California September 11, 2014. DreaMed Diabetes, the Petah Tikva-based developer of personalized diabetes management solutions, has received US Food and Drug Administration (FDA) clearance for its artificial intelligence-powered insulin recommendations technology. The company's AI-based insulin dosing decision-support software, DreaMed Advisor Pro, aims to assist people with Type 1 diabetes (T1D) using insulin-pump therapy with continuous glucose sensors or blood glucose meters.